Bristol-Myers Squibb Co. (NYSE:BMY)

CAPS Rating: 4 out of 5

Bristol-Myers Squibb discovers, develops, licenses, makes, and sells pharmaceuticals, with particular success in cardiovascular treatments.

Results 1 - 20 of 223 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar afewgoodstocks14 (< 20) Submitted: 10/1/2014 2:23:35 PM : Outperform Start Price: $50.52 BMY Score: -3.18

Div. (Yield) $1.44 (2.8%)

Recs

0
Member Avatar Herbstmd (51.49) Submitted: 8/22/2014 11:55:42 AM : Outperform Start Price: $49.68 BMY Score: +4.19

Developing great new cancer drugs called PD1, which may revolutionize cancer therapy.

Recs

0
Member Avatar Kenji94 (21.08) Submitted: 8/19/2014 1:29:19 AM : Underperform Start Price: $49.81 BMY Score: -3.21

There is a disconnection between price and fundamentals. I would like to own the company, but not at this price.

Recs

0
Member Avatar hydn (< 20) Submitted: 5/16/2014 10:28:57 AM : Outperform Start Price: $48.08 BMY Score: +1.17

Solid demand for ever improving products.

Recs

0
Member Avatar Johnybe (66.48) Submitted: 5/14/2014 9:46:28 PM : Outperform Start Price: $48.80 BMY Score: +0.53

strong player in this sector

Recs

0
Member Avatar DRGRNR (< 20) Submitted: 4/15/2014 7:52:17 PM : Outperform Start Price: $47.73 BMY Score: +1.09

I've owned BMY for 30 years, always a strong performer.

Recs

0
Member Avatar bassnman45 (33.82) Submitted: 1/2/2014 9:30:25 PM : Outperform Start Price: $20.86 BMY Score: +82.69

buy, hold long term and monitor

Recs

1
Member Avatar johnclanaro (< 20) Submitted: 10/28/2013 3:54:27 PM : Outperform Start Price: $50.68 BMY Score: -10.58

recent upgrade. good pipeline.

Recs

0
Member Avatar biostrategy (< 20) Submitted: 10/24/2013 12:58:47 PM : Underperform Start Price: $47.91 BMY Score: +5.48

Paten expiry coupled with a P/E of 52 does not bode well to a mature pharma concern.

Recs

1
Member Avatar gilmomp1 (47.23) Submitted: 10/16/2013 9:38:21 PM : Outperform Start Price: $47.23 BMY Score: -6.43

I bought 100 shares of this company pre 1995 and now own 188 shares by reinvesting my dividends. Now that I'm nearing retirement that dividend looks pretty good!

Recs

1
Member Avatar nancytroi (< 20) Submitted: 10/2/2013 11:43:34 AM : Outperform Start Price: $45.37 BMY Score: -3.89

Continues finding new drugs to fight cancers

Recs

0
Member Avatar lg7691 (23.00) Submitted: 7/21/2013 1:34:10 PM : Outperform Start Price: $42.71 BMY Score: +3.58

7/21/13 44.19 drug stock

Recs

2
Member Avatar usubanas (99.63) Submitted: 5/15/2013 2:35:44 AM : Outperform Start Price: $40.43 BMY Score: +7.18

I'm buying this tomorrow because of PD-1

Recs

0
Member Avatar DonkeyJunk (32.95) Submitted: 5/5/2013 10:39:09 PM : Underperform Start Price: $38.41 BMY Score: -11.19

Stock with a PE of almost 50 in an on-average overvalued market due for a significant pullback. With a company this size, the increase in revenue would have to be astronomical to justify the price.

Recs

0
Member Avatar mfwatcher (< 20) Submitted: 2/9/2013 10:45:25 AM : Outperform Start Price: $34.99 BMY Score: +16.35

Product pipeline has it positioned to outperform its peers during the recovery period.

Recs

0
Member Avatar HP2006 (79.14) Submitted: 1/28/2013 12:57:26 AM : Outperform Start Price: $34.35 BMY Score: +17.72

pharma

Recs

0
Member Avatar jrgyardley (< 20) Submitted: 12/17/2012 6:45:49 PM : Outperform Start Price: $30.83 BMY Score: +28.92

Sector
Patent expirations

Recs

0
Member Avatar TMFHelical (99.00) Submitted: 11/13/2012 9:54:12 AM : Outperform Start Price: $29.99 BMY Score: +28.11

One of the leaders of an annual industry audit that looks at value creation in the biotech space.

http://caps.fool.com/Blogs/a-look-at-established-biotech/774287

Recs

0
Member Avatar getoffmyfoot (58.95) Submitted: 11/5/2012 11:37:46 PM : Outperform Start Price: $31.19 BMY Score: +25.42

Can dividend reinvestment factor into this pick? Love the yield.

Recs

0
Member Avatar Marlonito9 (< 20) Submitted: 11/4/2012 6:31:37 PM : Underperform Start Price: $31.95 BMY Score: -24.37

This will underperform the S&P 500 because it is too strong.

Featured Broker Partners


Advertisement